Biomarkers and Biosimilars in Diabetes

Biosimilars are biological medical products/molecules which are almost identical copies of an original product manufactured by different companies and an already FDA-approved biological product, referred to as a reference product.  Human bio monitoring (HBM) is a tool of health-related environmental monitoring.

Diabetes is a major lifestyle disease, It is necessary to identify potential biomarkers associated with diabetes for early detection and proper management of diabetes.  Biomarkers are known as signature molecules or molecular markers or biological molecules found in blood, tissues and other body fluids. Biomarkers are used to monitor how well the body is responding to a particular disease. Hemoglobin A1c is considered as a biomarker for the presence of Diabetes Mellitus biosimilars in diabetes.

  • Scope and Role of Biomarkers
  • Biomarker Application in diabetes research
  • Novel Biomarkers
  • Biosimilar Development, Review, and Approval
  • Biosimilar and Interchangeable Products
  • Prescribing Biosimilar and Interchangeable Products
  • Biosimilar Product Information

Related Conference of Biomarkers and Biosimilars in Diabetes

September 09-10, 2024

7th Annual Meeting on Diabetes and Endocrinology

Paris, France
September 09-10, 2024

33rd International Diabetes and Healthcare Conference

Paris, France
September 09-10, 2024

4th European Endocrinology and Diabetes Congress

Paris, France
September 25-26, 2024

5th World Summit on Diabetes Expo

Rome, Italy
October 14-15, 2024

3rd International Summit on Hormonal Disorders

Madrid, Spain
November 22-23, 2024

20th World Congress on Endocrinology & Diabetes

Amsterdam, Netherlands
February 24-25, 2025

34th European Diabetes Congress

London, UK

Biomarkers and Biosimilars in Diabetes Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in